Previous 10 | Next 10 |
New data show rising burden of most cardiovascular risk factors among young adults aged 20 to 44 in the U.S. Findings are “extremely concerning” as expert notes “we’re witnessing a smoldering public health crisis” HeartBeam has developed the first and only 3...
HeartBeam (NASDAQ: BEAT) , a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, is reporting its operational and financial results for the fourth quarter and full year, ended Dec. 31, 2022. The...
2023-03-17 01:07:28 ET The following slide deck was published by HeartBeam, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: HeartBeam, Inc. 2022 Q4 - Results - Earnings Call Presentation
2023-03-17 01:06:05 ET HeartBeam, Inc. (BEAT) Q4 2022 Results Earnings Conference Call March 16, 2023, 04:30 PM ET Company Participants Branislav Vajdic - Founder and Chief Executive Officer Robert Eno - President Richard Brounstein - Chief Financial Officer ...
2023-03-16 16:14:49 ET HeartBeam press release ( NASDAQ: BEAT ): FY GAAP EPS of -$1.59 beats by $0.01 . Cash totaled $3.6 million as of December 31, 2022, compared to $13.2 million as of December 31, 2021. For further details see: HeartBeam GAAP EPS of -$...
Acquired Assets from LIVMOR, Extending Reach in Remote Monitoring and Detection with an Existing Cutting Edge FDA-Cleared Product, Halo+™ Atrial Fibrillation Detection System Partnered with Evolve Manufacturing to Build HeartBeam AIMIGo 12-Lead 3D Vector Electrocardiogram Device ...
Extends HeartBeam’s Reach with FDA-cleared Halo+™ Atrial Fibrillation Detection System and Physician-prescribed Integrated Patient Care Platform HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogr...
HeartBeam (NASDAQ: BEAT) is a cardiac technology company dedicated to finding effective ways to detect heart attacks earlier than ever before. “The company has two patented products in development: HeartBeam AIMI(TM), software for acute care settings that provides a 3D comparison of basel...
HeartBeam (NASDAQ: BEAT) , a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, has made key leadership changes. The company announced that HeartBeam president Robert Eno has been appointed exe...
Robert Eno Assumes Duties of Chief Business Officer Jon Hunt to Remain Strategic Advisor & Consultant to HeartBeam HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart att...
News, Short Squeeze, Breakout and More Instantly...
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has been added to the Russell Microcap(R) Index. The move was effective after market close on June 28, 2024, and is part of FTSE Russell’s annual reconst...
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced that it has been added to the Russell Microcap® Index effective after the market close on June 28, 2024 as part of FTSE Russell...
HeartBeam (NASDAQ: BEAT) , a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced the results of a new study demonstrating that HeartBeam AI combined with vectorcardiography (“VCG”) outperformed an expert panel o...